A Phase 4 interventional study of Infanrix™ penta and Infanrix™ hexa in Poliomyelitis, Acellular Pertussis and Tetanus, sponsored by GlaxoSmithKline. Completed at 3 sites in Russian Federation. Open to participants aged 18 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Poliomyelitis.
Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, this one is the 11th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 4, and was the 4th registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →None of the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis is open now. The open studies under Poliomyelitis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2008.
This study's enrollment of 283 is below the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 467 across the 14 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
44 studies in Poliomyelitis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 30 (70%) have results posted.
Among the 44 studies in Poliomyelitis by GlaxoSmithKline, this one is the 29th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2008, is one of 10 in phase 4, and was the 11th registered.
GlaxoSmithKline’s Poliomyelitis studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 44 in Poliomyelitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The new formulation administered as a 4th consecutive dose will be compared to the current formulation of the vaccine in this partially double blind study.
The study will be double-blind with respect to the two DTPa-HBV-IPV/Hib groups. The study will be open with respect to the DTPa-HBV-IPV group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
Biological: Infanrix™ hexa
Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
Biological: Infanrix™ hexa
Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
Biological: Infanrix™ penta
Subjects received a booster dose
Also known as: Pediarix
Subjects received a booster dose
Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose
Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)
Time frame: One month after the booster dose
Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose
Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)
Time frame: One month after the booster dose
Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose
Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)
Time frame: One month after the booster dose
Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose
Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)
Time frame: One month after the booster dose
Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose
Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)
Time frame: One month after the booster dose
Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose
Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes
Time frame: Before (Pre) and one month after (Post) the booster dose
Anti-HB Antibodies Concentration
Concentration of anti-HB antibodies given as GMC in mIU/mL
Time frame: Before (Pre) and one month after (Post) the booster dose
Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose
Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes
Time frame: Before (Pre) and one month after (Post) the booster dose
Anti-PRP Antibodies Concentration
Concentration of anti-PRP antibodies given as GMC in µg/mL
Time frame: Before (Pre) and one month after (Post) the booster dose
Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose
Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL
Time frame: Before the booster dose administration (at baseline)
Anti-diphtheria and Anti-tetanus Antibodies Concentration
Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL
Time frame: Before (Pre) and one month after (Post) the booster dose
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose
Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL
Time frame: Before (Pre) and one month after (Post) the booster dose
Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose
Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL
Time frame: Before the booster dose administration (at baseline)
Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose
Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50
Time frame: Before the booster dose
Anti-poliovirus Antibodies Titer
Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)
Time frame: Before (Pre) and one month after (Post) the booster dose
Number of Subjects Reporting Solicited Symptoms
Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite
Time frame: Within the 4-day (Day 0-3) post-vaccination period
Number of Subjects Reporting Unsolicited Adverse Events (AE)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Within the 31-day (Day 0-30) post-vaccination period
Number of Subjects Reporting Serious Adverse Events (SAE)
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above
Time frame: Up to one month after the booster dose administration
| Milestone | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Started | 111 | 115 | 57 |
| Completed | 110 | 114 | 56 |
| Not completed | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose | 88 | 92 | 48 |
Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose | 74 | 78 | 27 |
Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-diphtheria | 76 | 76 | 40 |
| Anti-tetanus | 76 | 78 | 42 |
Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-poliovirus type 1 | 55 | 51 | 31 |
| Anti-poliovirus type 2 | 55 | 51 | 30 |
| Anti-poliovirus type 3 | 55 | 52 | 29 |
Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)
| EL.U/mL | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-PT | 65.5 (49.8 to 86.3) | 84.2 (61.5 to 115.4) | 43.9 (22.4 to 85.8) |
| Anti-FHA | 476.6 (369.7 to 614.4) | 428.3 (311.2 to 589.5) | 221.1 (120.3 to 406.6) |
| Anti-PRN | 418.1 (303.2 to 576.6) | 384.1 (271.3 to 544.0) | 251.6 (143.9 to 439.7) |
Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| ≥ 10 mIU/mL Pre | 87 | 86 | 44 |
| ≥ 100 mIU/mL Pre | 57 | 57 | 35 |
| ≥ 100 mIU/mL Post | 85 | 87 | 39 |
Concentration of anti-HB antibodies given as GMC in mIU/mL
| mIU/mL | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Pre | 163.5 (114.3 to 233.7) | 161.2 (111.5 to 232.9) | 196.9 (124.2 to 312.2) |
| Post | 4668.0 (2861.4 to 7615.3) | 4962.3 (3289.7 to 7485.4) | 3867.8 (1751.4 to 8541.5) |
Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| ≥ 0.15 µg/mL Pre | 55 | 55 | 23 |
| ≥ 1.0 µg/mL Pre | 12 | 14 | 7 |
| ≥ 1.0 µg/mL Post | 69 | 74 | 9 |
Concentration of anti-PRP antibodies given as GMC in µg/mL
| µg/mL | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Pre | 0.3 (0.2 to 0.4) | 0.4 (0.3 to 0.5) | 0.2 (0.1 to 0.4) |
| Post | 25.3 (16.0 to 40.0) | 34.7 (22.9 to 52.7) | 0.4 (0.2 to 0.7) |
Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-diphtheria | 45 | 47 | 23 |
| Anti-tetanus | 69 | 62 | 39 |
Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL
| IU/mL | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-diphtheria Pre | 0.2 (0.1 to 0.2) | 0.2 (0.1 to 0.3) | 0.1 (0.1 to 0.2) |
| Anti-diphtheria Post | 2.7 (1.9 to 3.7) | 3.4 (2.5 to 4.5) | 2.2 (1.4 to 3.5) |
| Anti-tetanus Pre | 0.5 (0.3 to 0.6) | 0.5 (0.3 to 0.7) | 0.3 (0.2 to 0.4) |
| Anti-tetanus Post | 4.9 (3.6 to 6.7) | 6.9 (5.3 to 9.0) | 4.5 (2.8 to 7.4) |
Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-PT Pre | 45 | 43 | 26 |
| Anti-PT Post | 79 | 66 | 25 |
| Anti-FHA Pre | 77 | 68 | 39 |
| Anti-FHA Post | 86 | 69 | 37 |
| Anti-PRN Pre | 75 | 67 | 35 |
| Anti-PRN Post | 88 | 77 | 40 |
Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL
| EL.U/mL | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-PT | 6.6 (5.2 to 8.4) | 6.2 (5.0 to 7.8) | 7.1 (5.3 to 9.4) |
| Anti-FHA | 24.5 (18.4 to 32.6) | 22.1 (16.3 to 30.0) | 23.8 (17.3 to 32.6) |
| Anti-PRN | 17.5 (13.4 to 23.0) | 13.7 (10.3 to 18.1) | 15.0 (10.3 to 21.9) |
Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-poliovirus type 1 | 46 | 47 | 24 |
| Anti-poliovirus type 2 | 46 | 48 | 26 |
| Anti-poliovirus type 3 | 47 | 48 | 23 |
Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)
| titer | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Anti-poliovirus type 1 Pre | 106.5 (67.9 to 167.0) | 120.4 (76.9 to 188.4) | 85.9 (47.1 to 156.5) |
| Anti-poliovirus type 1 Post | 1237.1 (940.7 to 1626.9) | 1939.8 (1465.1 to 2568.2) | 979.5 (539.4 to 1778.8) |
| Anti-poliovirus type 2 Pre | 144.4 (96.9 to 215.2) | 102.5 (68.2 to 154.2) | 95.3 (56.3 to 161.1) |
| Anti-poliovirus type 2 Post | 1412.0 (1096.4 to 1818.5) | 1900.6 (1399.7 to 2580.7) | 916.3 (498.1 to 1685.5) |
| Anti-poliovirus type 3 Pre | 98.7 (68.0 to 143.2) | 68.9 (47.0 to 101.1) | 77.5 (41.9 to 143.4) |
| Anti-poliovirus type 3 Post | 1485.9 (1041.4 to 2120.3) | 1828.7 (1303.8 to 2565.1) | 605.6 (264.0 to 1389.1) |
Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Pain | 35 | 36 | 14 |
| Redness | 54 | 54 | 22 |
| Swelling | 39 | 45 | 19 |
| Drowsiness | 21 | 18 | 8 |
| Fever | 18 | 15 | 6 |
| Irritability | 21 | 21 | 4 |
| Loss of appetite | 22 | 14 | 5 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AE) | 8 | 9 | 2 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above
| subjects | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAE) | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix Hexa Preservative-free Formulation Group | 0/111 (0%) | 0/111 (0%) | 59/111 (53.2%) |
| Infanrix Hexa Preservative-containing Formulation Group | 0/115 (0%) | 0/115 (0%) | 62/115 (53.9%) |
| Infanrix Penta Preservative-free Formulation Group | 0/57 (0%) | 0/57 (0%) | 26/57 (45.6%) |
| Event | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group |
|---|---|---|---|
| RednessGeneral disorders | 54/111 | 54/115 | 22/57 |
| SwellingGeneral disorders | 39/111 | 45/115 | 19/57 |
| PainGeneral disorders | 35/111 | 36/115 | 14/57 |
| Loss of appetiteGeneral disorders | 22/111 | 14/115 | 5/57 |
| DrowsinessGeneral disorders | 21/111 | 18/115 | 8/57 |
| IrritabilityGeneral disorders | 21/111 | 21/115 | 4/57 |
| FeverGeneral disorders | 18/111 | 15/115 | 6/57 |
| Age, Continuous(months) | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group | Total |
|---|---|---|---|---|
| Mean | 21.2 ± 1.61 | 21.3 ± 1.57 | 21.2 ± 1.62 | 21.2 ± 1.59 |
| Sex: Female, Male(Participants) | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group | Total |
|---|---|---|---|---|
| Female | 56 | 46 | 35 | 137 |
| Male | 55 | 69 | 22 | 146 |
| Race/Ethnicity, Customized(Participants) | Infanrix Hexa Preservative-free Formulation Group | Infanrix Hexa Preservative-containing Formulation Group | Infanrix Penta Preservative-free Formulation Group | Total |
|---|---|---|---|---|
| White - Caucasian/European Heritage | 111 | 115 | 57 | 283 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Feb 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine